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SUMMARY
The induction of expression of the components of the proteolytic plasminogen activation system in cutaneous melanocytic tumour 
progression has previously been reported. Plasminogen activators, their inhibitors, and the receptor for urokinase were present only in 
advanced primary melanomas and melanoma metastases. The present study reports on the presence of tetranectin and plasmin/ 
plasminogen, two proteins connected with plasminogen activation, in cutaneous melanocytic lesions. The distribution of tetranectin and 
plasminogen was studied by immunohistochemistry in 105 freshly frozen melanocytic lesions of common naevocellular naevi («=24), 
atypical naevi (/i=14), early (« = 12) and advanced («=20) primary melanomas, and melanoma metastases («=35). Both tetrancctin and 
plasminogen were detected in a variety of tissue components. In all stages of melanocytic tumour progression, tetranectin was found in 
endothelium, perivascular dendritic cells, and leukocytes. Plasminogen was present in endothelium and in the basal layer of the normal 
skin. Tetranectin and plasminogen staining of fibroblastic cells at the invasive front and of extracellular matrix was, however, restricted 
to malignant lesions. Co-localization of tetranectin and plasminogen was found in 50 per cent of the early primary melanomas and in 
more than 75 per cent of the advanced melanomas and melanoma metastases. These results suggest a coordinated role for tetranectin 
and plasminogen at the invasive front of melanomas. Tetranectin-bound plasminogen may facilitate the migration of tumour cells.
KEY w o r d s — melanoma; skin; tetranectin; plasminogen; plasminogen activation; immunohistochemistry; co-localization
INTRODUCTION
In the concept o f tumour cell invasion and metastasis, 
the degradation of tissue barriers has been implicated, In 
this process, several proteolytic enzyme systems can be 
recruited ; 1*2 one system involved in tumour spread is 
plasminogen activation . 3*4 In vitro5 and in vivo6'* find­
ings indicate that both tum our cells and fibroblastic 
stromal cells are involved in the plasminogen activation 
process at the tum our-strom a interface . 9 In cutaneous 
melanoma lesions, urokinase plasminogen activator 
(u-PA) in particular is markedly present in tumour 
cells8 J 0  and in stromal cells8 at the periphery of tumour 
nodules.
Two other molecules which are involved in the process 
of plasminogen activation and which play a putative role 
in the migration process o f tum our cells are plasminogen 
and tetranectin. Tetranectin is a 6 8  kD protein purified 
from plasma, which binds to the kringle 4 domain of 
plasminogen . 13 Plasma of cancer patients contains sig­
nificantly lower levels of tetranectin compared to age- 
and sex-matched control groups . 12-14 Tetranectin is 
present in a variety of cells, including monocytes , 15
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neutrophils , 16 and fibroblasts . 17 In breast , 18 ovarian , 14 
and colonic19,20 tumours, tetranectin is present in the 
stroma surrounding the tumour. Moreover, plasma 
tetranectin content and stromal immunoreactivity are of 
prognostic relevance in patients with ovarian cancer. 14
Plasminogen is the substrate for plasminogen acti­
vators. Cleavage of plasminogen by plasminogen 
activators forms the active enzyme plasmin. Little is 
known about the presence of plasmin/plasminogen in 
cancerous tissues. In colonic carcinomas, it is reported 
to be present in stromal cells.21
Recently, we described the presence of the compo­
nents of the plasminogen activation system in advanced 
stages o f hum an cutaneous melanocytic tumour progres­
sion .8 Here, we present data on the distribution of 




Representative tissue samples were freshly received 
from cutaneous melanocytic lesions excised from 
patients at the University Hospital, Nijmegen, The 
Netherlands, and from patients at the University 
Hospital, Wurzburg, Germany. They were snap-frozen 
in liquid nitrogen and stored at — 80°C until sectioning. 
Based on conventional histopathological examination of 
paraffin sections, lesions were divided into five classes: 
common naevocellular naevus (NN, n= 24), atypical
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naevus (AN, n - 14), early primary melanoma (Breslow 
thickness <1*5 mm) (ePM, 77= 12), advanced primary 
melanoma (Breslow thickness >1-5 mm) (aPM, «=20), 
and melanoma metastasis (MM, n= 35).
Antibodies
Tw o well-characterized antibodies were used. Rabbit 
polyclonal antibody A371 against tetranectin11 has been 
used previously in immunohistochemistry. Staining 
with this polyclonal antibody compared well to the 
staining obtained with a monoclonal antibody against
tetranectin . 18’22
R abb it polyclonal antibody against plasminogen/ 
plasmin was affinity-purified by passaging through a 
Sepharose column to which the kringle 1-3 part of 
plasminogen was coupled. Others have shown that 
immunohistochemical staining of tissue sections with 
this antibody compares well to various monoclonal 
and  polyclonal antibodies against plasmin/plasminogen 
(Christensen et al., paper submitted).
Immunohis to chemis try
The immunohistochemical staining procedure for 
polyclonal antibodies was as described previously . 8 
Briefly, 4 f im cryostat sections were air-dried overnight 
a t  ro o m  temperature and stored at — 80°C until use. 
A fter acetone fixation, dilutions of the polyclonal anti­
bodies were applied to the sections. Antibody bind­
ing was visualized with a peroxidase-labelled swine 
an ti-rabbit secondary antibody and incubation with 
3-amino-9-ethylcarbazole as a substrate for peroxidase. 
A fter counterstaining the nuclei with Papanicolaou’s 
H arris  solution, sections were mounted with Kaiser’s 
glycerin (Merck, Darmstadt, Germany). An incubation 
in which the first antibody was omitted served as a 
negative control. Consecutive sections of the same lesion 
were incubated with the tetranectin and plasminogen 
antibodies. Localization similarities were judged by 
com paring  the staining results of the two sections.
Score
F o r  each section, the percentage of positive melano- 
cytic cells was estimated. Each section was assigned to 
one o f the following categories: 0 per cent, 1-5 per cent, 
6-25 per cent, and 26-100 per cent positivity. Positive 
melanocytic staining was registered when at least 
I per cent of the melanocytic cells stained. Notes were 
taken of other staining components (fibroblast-like cells, 
extracellular matrix) among the melanocytic areas. 
Sections were scored independently by two observers 
(T, J. de V., P. E. J. de W.). Discrepancies were found in 
fewer than 10 per cent o f the lesions. These cases were 
re-evaluated jointly until agreement was reached.
RESULTS
Tissue sections of naevocellular naevi, atypical naevi, 
early and  advanced primary melanomas, and melanoma
metastases were stained for tetranectin and plasm ino­
gen. Typical examples of tetranectin and  plasminogen 
staining are shown in Figs 1 and 2 .
Tetranectin
The various aspects o f tetranectin staining are sum ­
marized in Table I. Tetranectin was localized in a  variety 
o f cell types. In benign common naevocellular naevi an d  
in atypical naevi, there were scattered positively stained 
cells in the dermis, so-called perivascular dendritic cells21 
(Fig. la). In addition, some blood vessels showed posi­
tive endothelium (not shown). Tetranectin-positive 
cells were often found in the lumen of blood vessels, in 
both benign and malignant lesions (Fig. lb). Staining o f  
the extracellular matrix surrounding tum our cells was 
observed in primary melanomas and metastases only. 
Fibroblastic cells either did not stain, or stained weakly 
in benign lesions, Staining of the strom a was frequently 
observed in malignant lesions and was m uch m ore 
pronounced, especially a t the invasive front (Fig. Ik). 
N o  tetranectin staining o f melanocytic cells was encoun­
tered in the benign lesions and tetranectin staining o f  
tum our cells was seen in very few m alignant lesions 
(Fig. 2a). Staining mainly in the 1-5 per cent category 
was found in 1 / 1 2  o f  the early primary tumours, in 1 / 2 0  
of the advanced primary melanomas and in 4/35 o f the 
metastatic lesions. One advanced primary m elanom a 
contained 6-25 per cent tetranectin-positive cells.
Plasminogen
The various aspects o f plasminogen staining are sum ­
marized in Table II. Plasminogen was found in the basal 
cell layer of the epidermis, both in benign and in 
malignant lesions (Fig. lc). This staining was often m ore 
pronounced towards the basal m em brane (not shown). 
In all types of lesions studied, there was staining of the 
endothelium of blood vessels (not shown). The extra­
cellular matrix around tum our cells stained in m any 
advanced primary melanomas and in various metastases 
(Fig. le). Staining of extracellular matrix was m ore often 
seen, and more intense than in the case of tetranectin. 
N o  staining or weak staining o f  fibroblastic cells was 
encountered in benign lesions and stronger staining o f  
the stroma, markedly at the tum our-s trom a interface 
(Figs li  and lj), was found in primary m elanom a and in 
melanoma metastases.
Plasminogen staining o f melanocytic cells was absent 
in the common naevocellular naevi and in the atypical 
naevi, whereas some o f  the malignant lesions (Fig. 2b) 
showed positivity. T um our cell staining was encountered 
in only a few cases of primary m elanom a and m elanom a 
metastases. This staining, mainly in the 1-5 per cent 
category, was present in 0 / 1 2  o f  the early prim ary 
tumours, in 1 / 2 0  o f  the advanced prim ary  m elanom as 
and  in 7/35 o f the metastatic lesions. One advanced 
primary melanoma and one metastasis contained 
6-25 per cent plasminogen-positive cells.
Co-localization o f tetranectin and plasminogen
In the majority of malignant lesions, tetranectin an d  
plasminogen were found in corresponding cell types or
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Table II—Plasminogen/plasmin staining in melanocytic lesions
Cell type/structure NN AN ePM aPM MM Remarks
Melanocytic cells — — + + + Positivity in a low percentage 
of cells in only 12  per cent 
of the malignant lesions
Fibroblast-like cells ~ l ± - / ± + + Absent or very weak staining 
in NN and AN. Frequent 
and pronounced staining, 
mainly at the 
tumour-stroma interface, 
in most PMs and MMs
Extracellular matrix + "h + Positivity around tumour 
cells in a few ePMs and 
many aPMs and MMs
Endothelial cells + + + + + Positivity in part of the 
blood vessels
Basal keratinocytes + + Él^M + NP
Leukocytes (in blood vessels) + Hr + + +
N N ^com m on naevocellular naevus; AN^atypical naevus; ePM=early primary melanoma; aPM=advanced primary 
melanoma; MM = melanoma metastasis; NP = not present in these lesions.
— =no staining; ± =faint staining; + =clear staining.
Table III—Co-localization of tetranectin and plasmin/ 
plasminogen in malignant melanocytic lesions
Type of lesions
No. of cases with 
co-localization 





Early primary melanoma 6 12
Advanced primary melanoma 18 20
Melanoma metastases 27 38
and not in the tum our cells of colonic cancer. Cultured 
embryonic fibroblasts also deposit tetranectin . 17
Tetranectin staining a t the invasive front has been 
described for various tumours. M any authors have 
speculated about the role of tetranectin in tumour cell 
migration at the periphery o f the tum our . 14»18»20 
Recently, Nielsen et a l [S showed that secreted tetranec­
tin can facilitate migration of monocytes. Similarly, one 
can envisage that fibroblasts at the tum our edge which 
produce tetranectin might attract tum our cells in a 
paracrine fashion. Tetranectin increases plasminogen 
activation by tissue-type plasminogen activator (t-PA).u 
It is of interest that tum our cells in melanoma lesions 
show an enhanced expression of t-PA .8*10*30 In this 
respect, melanoma differs from other tumours, as t-PA- 
associated tum our cell staining is hardly seen in non­
melanoma tumours.
With respect to the ‘fine tuning5 of proteolytic activity, 
it was recently described that both t-PA binding sites31 
and u-PA receptor32 are in close proximity to the 
receptor for plasminogen. We believe tha t in melano­
cytic tumours, plasminogen activation is a process local­
ized at the tum our-strom a interface. Previously, it was 
described that u-PA protein8 and activity10 are present 
at the invasive front in melanoma lesions. The
co-localization of plasminogen and tetranectin strongly 
suggests an anchorage role for tetranectin. Tetranectin- 
bound plasminogen could well serve as a feeder layer for 
plasminogen activator-positive migrating tumour cells. 
In vitro experiments are needed to test this hypothesis.
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